Updated Jul 16, 2026 · Last SEC filing 2026-07-03
Spyre Therapeutics, Inc. (SYRE) has filed 19 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-07-03. 4 Form 8-K material event filings were reported by SYRE in the last 90 days. 8 Form 144 notices of proposed sale were filed for SYRE stock. InsiderAlpha tracks every SYRE SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.
| SEC CIK | 0001636282 |
|---|
| Form 4 filings (90d) | 19 |
|---|---|
| Form 8-K filings (90d) | 4 |
| Form 144 notices (90d) | 8 |
| Latest Form 4 filing | 2026-07-03 |
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Burrows Scott L | Chief Financial Officer | S — Open-market sale | 1.7K | $88.37 | $152K | SEC | |
| Turtle Cameron | Chief Executive Officer | S — Open-market sale | 590 | $88.91 | $52K | SEC | |
| Sloan Sheldon | Chief Medical Officer | S — Open-market sale | 6.5K | $87.52 | $569K | SEC | |
| Sloan Sheldon | Chief Medical Officer | M — Option exercise | 8.3K | $27.46 | $229K | SEC | |
| Turtle Cameron | Chief Executive Officer | S — Open-market sale | 4.2K | $88.12 | $373K | SEC | |
| Turtle Cameron | Chief Executive Officer | S — Open-market sale | 10.2K | $87.44 | $890K | SEC | |
| Sloan Sheldon | Chief Medical Officer | S — Open-market sale | 1.8K | $88.34 | $162K | SEC | |
| Burrows Scott L | Chief Financial Officer | S — Open-market sale | 5.8K | $87.55 | $506K | SEC | |
| Burrows Scott L | Chief Financial Officer | M — Option exercise | 7.5K | $14.50 | $109K | SEC | |
| Burrows Scott L | Chief Financial Officer | S — Open-market sale | 10.0K | $87.14 | $871K | SEC | |
| Burrows Scott L | Chief Financial Officer | M — Option exercise | 15.0K | $14.50 | $218K | SEC | |
| Burrows Scott L | Chief Financial Officer | S — Open-market sale | 5.0K | $87.12 | $436K | SEC | |
| Fairmount Funds Management LLC | Director | J — Other acquisition / disposition | 666.7K | — | — | SEC | |
| Fairmount Funds Management LLC | Director | S — Open-market sale | 4.68M | $85.31 | $399.66M | SEC | |
| HENDERSON MICHAEL THOMAS | Director | S — Open-market sale | 20.0K | $100.00 | $2.00M | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for Spyre Therapeutics, Inc. (SYRE). Updated in real time as new filings are submitted to the SEC.
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| Sloan Sheldon | 16 | $9.57M |
| Burrows Scott L | 16 | $4.01M |
| Turtle Cameron | 12 | $3.44M |
| HENDERSON MICHAEL THOMAS | 6 | $7.95M |
| Fairmount Funds Management LLC | 4 | $399.66M |
Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in SYRE insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
Open the live SYRE dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.